{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.012","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.104","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"4.0"},{"groupId":"OG002","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"description":"The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants will continue to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"NUMBER","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using NRI.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of Participants Achieving ACR/EULAR Remission - Boolean Remission","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}